Bioline Rx Return on Assets:
-60.12% for March 31, 2013Bioline Rx Historical Return on Assets Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | -60.12% |
| Dec. 31, 2012 | -64.86% |
| Sept. 30, 2012 | -52.67% |
| June 30, 2012 | -39.28% |
| March 31, 2012 | -42.89% |
About Return on Assets
Return on Assets (ROA) shows the rate of return (after tax) being earned on all of the firm's assets regardless of financing structure (debt vs. equity). It is a measure of how efficiently the company is using all stakeholders' assets to earn returns.
Because ROA can differ significantly across firms, ROA is often used to compare a company over time or against companies that have similar financing structures.
Learn More
BLRX Return on Assets Benchmarks
| Companies | |
|---|---|
| Array BioPharma | -37.10% |
| Cytokinetics | -58.48% |
| Oramed Pharmaceuticals | -85.79% |
BLRX Return on Assets Rankings
| Overall |
42nd percentile 4623 of 8002 |
| Sector |
31st percentile 448 of 650 in Healthcare |
| Industry |
44th percentile 137 of 248 in Biotechnology |
BLRX Return on Assets Range, Past 5 Years
| Minimum | -64.86% | Dec 2012 |
| Maximum | -39.28% | Jun 2012 |
| Average | -51.96% |
BLRX News
BioLineRx (BLRX) Enrolls First Patients in BL-8020 Phase I/II as HCV Treatment
Street Insider Apr 29
Street Insider Apr 29
